Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine.

Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine. Vaccine. 2020 Jan 17;: Authors: Stinson JA, Palmer CR, Miller DP, Li AB, Lightner K, Jost H, Weldon WC, Oberste MS, Kluge JA, Kosuda KM Abstract Current inactivated polio vaccine (IPV) products are sensitive to both freezing and elevated temperatures and therefore must be shipped and stored between 2 °C and 8 °C, a requirement that imposes financial and logistical challenges for global distribution. As such, there is a critical need for a robust, thermally stable IPV to support global polio eradication and post-eradication immunization needs. Here, we present the development of air-dried thin films for temperature stabilization of IPV using the biomaterial silk fibroin. Thin-film product compositions were optimized for physical properties as well as poliovirus D-antigen recovery and were tested under accelerated and real-time stability storage conditions. Silk fibroin IPV films maintained 70% D-antigen potency after storage for nearly three years at room temperature, and greater than 50% potency for IPV-2 and IPV-3 serotypes at 45 °C for one year. The immunogenicity of silk fibroin IPV films after 2-week storage at 45 °C was assessed in Wistar rats and the stressed films generated equivalent neutralizing antibody responses to commercial vaccine for IPV-1 and IPV-2. However, the absence of IPV-3 responses warrants furth...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research

Related Links:

Poliomyelitis is a motor neuron disease of the anterior horn of the spinal cord. It leads to asymmetrical flaccid paralysis and muscle atrophy that reduces the patient's stability and mobility and alters the gait pattern, predisposing to falls. Until the massive clinical application of vaccines, it was quite prevalent in some countries in the 50s and, the people who suffered the epidemic during childhood is nowadays more than 65 years old, constituting a risk groups for traumatological pathology.
Source: Injury - Category: Orthopaedics Authors: Source Type: research
By Casey Bishopp, Communications officer, IntraHealth International ; Sabra Farquharson, Business development officer, IntraHealth InternationalFebruary 18, 2020We’re celebrating the legacies of ten African Americans in public health this month—shining a light on the invaluable contributions made by these scholars and health workers. According to themost recent report form the Health Resources and Services Administration, African Americans make up 11.6% of the US health workforce, and throughout American history have made invaluable contributions to greater public health in fields s...
Source: IntraHealth International - Category: International Medicine & Public Health Authors: Source Type: news
AbstractNearly 20 years after the year 2000 target for global wild poliovirus (WPV) eradication, live polioviruses continue to circulate with all three serotypes posing challenges for the polio endgame. We updated a global differential equation ‐based poliovirus transmission and stochastic risk model to include programmatic and epidemiological experience through January 2020. We used the model to explore the likely dynamics of poliovirus transmission for 2019–2023, which coincides with a new Global Polio Eradication Initiative Strategi c Plan. The model stratifies the global population into 72 blocks, each containi...
Source: Risk Analysis - Category: International Medicine & Public Health Authors: Tags: Original Research Article Source Type: research
The University of Pittsburgh ’s Center for Vaccine Research could have a specimen from the deadly SARS-CoV-2 coronavirus within the week in an effort by the world-renowned research institution to help create a vaccine. Pitt, where Dr. Jonas Salk created the polio vaccine, is one of the country’s leading biomedical research centers. The Center for Vaccine Research on the Pitt campus is designed to safely and efficiently handle some of the world’s most dangerous infectious diseases. It’s the…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
[WHO] Republic of Congo steps up polio vaccination in border region
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Condition:   Polio Interventions:   Biological: sIPV;   Biological: Commercialized sIPV;   Biological: Commercialized IPV Sponsors:   Jiangsu Province Centers for Disease Control and Prevention;   Beijing Minhai Biotechnology Co., Ltd Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Polio Intervention:   Biological: sIPV Sponsor:   Jiangsu Province Centers for Disease Control and Prevention Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Polio Interventions:   Biological: sIPV;   Biological: Commercialized sIPV;   Biological: Commercialized IPV Sponsors:   Jiangsu Province Centers for Disease Control and Prevention;   Beijing Minhai Biotechnology Co., Ltd Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Polio Intervention:   Biological: sIPV Sponsor:   Jiangsu Province Centers for Disease Control and Prevention Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy & Immunology | Polio | Polio Vaccine | Vaccines